Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer

Abstract Background Lenvatinib, programmed cell death 1 (PD-1) antibodies, and gemcitabine and oxaliplatin (GEMOX) chemotherapy have shown significant antitumor activity as first-line therapy against biliary tract cancer. This study evaluated their efficacy and safety as non-first-line therapy in ad...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yang Tan, Kai Liu, Chengpei Zhu, Shanshan Wang, Yunchao Wang, Jingnan Xue, Cong Ning, Nan Zhang, Jiashuo Chao, Longhao Zhang, Junyu Long, Xiaobo Yang, Daobing Zeng, Lijin Zhao, Haitao Zhao
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Springer 2024-10-01
coleção:	Cancer Immunology, Immunotherapy
Assuntos:	Gallbladder cancer Lenvatinib PD-1 GEMOX Chemotherapy Systemic therapy
Acesso em linha:	https://doi.org/10.1007/s00262-024-03831-1
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!